Biomarkers for psychiatry: The journey from fantasy to fact, a report of the 2013 CINP think tank

International Journal of Neuropsychopharmacology

Volumn 18, Issue 10, 2015, Pages

  Scarr, Elizabeth ^a,b   Millan, Mark J ^c   Bahn, Sabine ^d   Bertolino, Alessandro ^e,f   Turck, Christoph W ^g   Kapur, Shitij ^h   Möller, Hans Jürgen ⁱ   Dean, Brian ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF BARI   (Italy)

^g MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Animal studies; Biomarkers; Clinical samples; Imaging; Psychiatric disorders

Indexed keywords

BIOLOGICAL MARKER;

COHORT ANALYSIS; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; ECONOMICS; MENTAL DISORDERS; METABOLISM; PSYCHIATRY; TREATMENT OUTCOME;

BIOMARKERS; HUMANS; MENTAL DISORDERS; PSYCHIATRY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84928297914     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv042     Document Type: Review

References (70)

1. Andreou C, Bozikas VP (2013) The predictive signifcance of neu-rocognitive factors for functional outcome in bipolar disorder. Curr Opin Psychiatry 26:54-59.
2. Arnedo J, Svrakic DM, Del VC, Romero-Zaliz R, Hernandez-Cuervo H, Fanous AH, Pato MT, Pato CN, de Erausquin GA, Cloninger CR, Zwir I (2015) Uncovering the hidden risk architecture of the schizophrenias: confrmation in three independent genome-wide association studies. Am J Psych 172:139-153.
3. Barry MJ (2001) Prostate-specifc antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373-1377.
4. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC (2014) Infammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res 56:18-27.
5. Belzeaux R, Formisano-Tréziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Féron F, Naudin J, Ibrahim EC (2010) Clinical variations modulate patterns of gene expression and defne blood biomarkers in major depression. J Psychiatr Res 44:1205-1213.
6. Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC (2012) Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2:e185.
7. Bertolino A, Caforio G, Blasi G, De CM, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psych 161:1798-1805.
8. Bilello JA, Thurmond LM, Smith KM (2013) Use of the MDDScore biomarker panel for the detection of major depressive order in centralized intractable pain. Biol Psychiatry 75:261S.
9. Blasi G, De VC, Papazacharias A (2013) Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry 70:921-930.
10. Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N, Ram-baldelli G, Tansella M, Maria Finardi A, Martino G, Perlini C, Fur-lan R (2014) Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry 4:e406.
11. Bressa GM (1994) S-adenosyl-l-methionine (SAMe) as anti-depressant: meta-analysis of clinical studies. Acta Neurol Scand 89:7-14.
12. Brown NC, Andreazza AC, Young LT (2014) An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 218:61-68.
13. Buchhave P, Minthon L, Zetterberg H, Wallin Å, Blennow K, Hansson O (2012) Cerebrospinal fuid levels of ß-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of alzheimer dementia. Arch Gen Psychiatry 69:98-106.
14. Cross-Disorder Group of the Psychiatric Genomics Consortium (2013a) Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 45:984-994.
15. Cross-Disorder Group of the Psychiatric Genomics Consortium (2013b) Identifcation of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381:1371-1379.
16. Cumming G (2008) Replication and p intervals: p values predict the future only vaguely, but confdence intervals do much better. Perspect Psychol Sci 3:286-300.
17. de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS, Bahn S (2014) Cytokine alterations in frst-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res 154:23-29.
18. Dean B (2011a) Dissecting the syndrome of schizophrenia: progress toward clinically useful biomarkers. Schizophr Res Treatment Retrieved 29 Aug 2011. doi:10.1155/2011/614730:A rticle ID 614730.
19. Dean B (2011b) Understanding the role of infammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychop 14:997-1012.
20. Ditzen C, Varadarajulu J, Czibere L, Gonik M, Targosz BS, Hamb-sch B, Bettecken T, Kesler MS, Frank E, Bunck M, Teplytska L, Erhardt A, Holsboer F, Muller-Myhsok B, Landgraf R, Turck CW (2010) Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Mol Psychiatry 15:702-711.
21. Dourish CT, Dawson GR (2014) Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia (editorial). Biomark Med 8:5-8.
22. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased infammatory markers identifed in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:206-214.
23. Fusar-Poli P, Borgwardt S, Bechdolf A (2013) The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70:107-120.
24. Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J, Figuerido JL, de LJ (1998) First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Dis-ord 50:41-44.
25. Han K, Holder Jr JL, Schaaf CP, Lu H, Chen H, Kang H, Tang J, Wu Z, Hao S, Cheung SW, Yu P, Sun H, Breman AM, Patel A, Lu HC, Zoghbi HY (2013) SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503:72-77.
26. Heresco-Levy U, Gelfn G, Bloch B, Levin R, Edelman S, Javitt DC, Kremer I (2013) A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neu-ropsychop 16:501-506.
27. Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, Suetsugi M, Watanabe Y (2010) Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 44:263-270.
28. Iga Ji, Ueno Si, Yamauchi K, Numata S, Kinouchi S, Tayoshi-Shibuya S, Song H, Ohmori T (2007) Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 31:628-632.
29. The International Schizophrenia Consortium (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752.
30. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM (2011) Glycine and a glycine dehydroge-nase (GLDC) SNP as citalopram/escitalopram response bio-markers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89:97-104.
31. Kapur S, Phillips AG, Insel TR (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it[quest]. Mol Psychiatry 17:1174-1179.
32. Kauppi K, Westlye LT, Tesli M, Bettella F, Brandt CL, Mattingsdal M, Ueland T, Espeseth T, Agartz I, Melle I, Djurovic S, Andreas-sen OA (2014) Polygenic risk for schizophrenia associated with working memory-related prefrontal brain activation in patients with schizophrenia and healthy controls. Schizophr Bull Retrieved 16 Dec 2014. doi:10.1093/schbul/sbu152.
33. Kikuchi K, Iga Ji, Tayoshi S, Nakataki M, Watanabe S, Numata S, Ohmori T (2011) Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder. Hum Psychopharmacol Clin Exp 26:358-363.
34. Kinou M, Takizawa R, Marumo K, Kawasaki S, Kawakubo Y, Fukuda M, Kasai K (2013) Differential spatiotemporal characteristics of the prefrontal hemodynamic response and their association with functional impairment in schizophrenia and major depression. Schizophr Res 150:459-467.
35. Koutsouleris N, Meisenzahl EM, Davatzikos C, Bottlender R, Frodl T, Scheuerecker J, Schmitt G, Zetzsche T, Decker P, Reiser M, Möller HJ, Gaser C (2009) Use of neuroanatomical pattern classifcation to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry 66:700-712.
36. Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Möller HJ, Riecher-Rössler A (2012a) Disease prediction in the at-risk mental state for psychosis using neuroanatomi-cal biomarkers: results from the FePsy study. Schizophr Bull 38:1234-1246.
37. Koutsouleris N, Davatzikos C, Bottlender R, Patschurek-Kliche K, Scheuerecker J, Decker P, Gaser C, Möller HJ, Meisenzahl EM (2012b) Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classifcation. Schizophr Bull 38:1200-1215.
38. Kuzman MR, Medved V, Terzic J, Krainc D (2009) Genome-wide expression analysis of peripheral blood identifes candidate biomarkers for schizophrenia. J Psychiatr Res 43:1073-1077.
39. Lehman S (2014) Sometimes, ignorance really is bliss. In: The Globe and Mail, June 19th 2014 (Hayward K, ed.) pp L5. Toronto, Ontario: Phillip Crawley.
40. Liu ML, Zheng P, Liu Z, Xu Y, Mu J, Guo J, Huang T, Meng HQ, Xie P (2014) GC-MS based metabolomics identifcation of possible novel biomarkers for schizophrenia in peripheral blood mon-onuclear cells. Mol Biosyst. Retrieved 30 Jul 2014. doi: 10.1039/c4mb00157e
41. Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A, Lorberg B, Mane S, Zhao H, Sinha R, Bhagwagar Z, Beech R (2012) Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Biol Mood Anxiety Disord 2:15. Retrieved 31 Jul 2014. doi:10.1186/2045-5380-2-15.
42. Malhi GS, Tanious M, Gershon S (2011) The lithiumeter: a measured approach. Bipolar Disord 13:219-226.
43. Mamdani F, Berlim MT, Beaulieu MM, Labbe A, Merette C, Turecki G (2011) Gene expression biomarkers of response to citalo-pram treatment in major depressive disorder. Transl Psychiatry 1:e13.
44. Mamdani F, Martin MV, Lencz T, Rollins B, Robinson DG, Moon EA, Malhotra AK, Vawter MP (2013) Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia. Dis Markers 35:11-21.
45. Mastromauro C, Myers RH, Berkman B, Opitz JM, Reynolds JF (1987) Attitudes toward presymptomatic testing in Hunting-ton disease. Am J Med Genet 26:271-282.
46. Meiser B, Dunn S (2001) Psychological effect of genetic testing for Huntington's disease: an update of the literature. West J Med 174:336-340.
47. Millan MJ (2013) An epigenetic framework for neurodevelop-mental disorders: from pathogenesis to potential therapy. Neuropharmacology 68:2-82.
48. Millan MJ, et al. (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11:141-168.
49. Musliner KL, Seifuddin F, Judy JA, Pirooznia M, Goes FS, Zandi PP (2015) Polygenic risk, stressful life events and depressive symptoms in older adults: a polygenic score analysis. Psychol Med. 45; 1709-1720.
50. Neumar RW, et al. (2008) Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication a consensus statement from the international liaison committee on resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation 118:2452-2483.
51. Opmeer EM, Kortekaas R, van Tol MJ, van der Wee NJ, Woudstra S, van Buchem MA, Penninx BW, Veltman DJ, Aleman A (2013) Infuence of COMT val158met genotype on the depressed brain during emotional processing and working memory. PLOS ONE 8:e73290.
52. Poels EMP, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR (2014) Imaging glu-tamate in schizophrenia: review of fndings and implications for drug discovery. Mol Psychiatry 19:20-29.
53. Pukrop R, Schultze-Lutter F, Ruhrmann S, Brockhaus-Dumke A, Tendolkar I, Bechdolf A, Matuschek E, Klosterkotter J (2006) Neurocognitive functioning in subjects at risk for a frst episode of psychosis compared with frst-and multiple-episode schizophrenia. J Clin Exp Neuropsychol 28:1388-1407.
54. Rabinowitz J, Werbeloff N, Caers I, Mandel FS, Stauffer V, Ménard F, Kinon BJ, Kapur S (2014) Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J Clin Psychiatry 75:e308-e316.
55. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptors defne a subgroup of subjects with schizophrenia. Mol Psychiatry 14:1017-1023.
56. Schobel SA, Lewandowski NM, Corcoran CM (2009) DIfferential targeting of the ca1 subfeld of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 66:938-946.
57. Schwarz E, et al. (2010) Validation of a blood-based laboratory test to aid in the confrmation of a diagnosis of schizophrenia. Biomark Insights 5:39-47.
58. Schwarz E, van Beveren NJM, Ramsey J, Leweke FM, Rother-mundt M, Bogerts B, Steiner J, Guest PC, Bahn S (2014) Identi-fcation of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr Bull 40:787-795.
59. Stauffer VL, Millen BA, Andersen S, Kinon BJ, LaGrandeur L, Lin-denmayer JP, Gomez JC (2013) Pomaglumetad methionil: no signifcant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 150:434-441.
60. Stelzhammer V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H, Martins-de-Souza D, Rahmoune H, Guest PC, Bahn S (2014) Proteomic changes in serum of frst onset, antidepressant drug-naïve major depression patients. Int J Neuropsychop 17:1599-1608.
61. Sullivan PF, Daly MJ, O'Donovan M (2012) Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 13:537-551.
62. Tamminga CA (2008) Accelerating New Knowledge in Schizophrenia. Am J Psych 165:949-951.
63. Tansey KE, et al. (2012) Genetic predictors of response to sero-tonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLOS Med 9:e1001326.
64. Trivedi MH, Greer TL (2014) Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord 152-154:19-27.
65. Ursini G, Bollati V, Fazio L, Porcelli A, Iacovelli L, Catalani A, Sinibaldi L, Gelao B, Romano R, Rampino A, Taurisano P, Mancini M, Di Giorgio A, Popolizio T, Baccarelli A, De Blasi A, Blasi G, Bertolino A (2011) Stress-related methylation of the catechol-o-methyltransferase Val158 allele predicts human prefrontal cognition and activity. J Neurosci 31:6692-6698.
66. US Food and Drug Administration (2013) Information for healthcare professionals: dangerous or even fatal skin reactions-carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). Silver Spring, MD: US Food and Drug Administration.
67. Vaz-Luis I, Winer EP, Lin NU (2013) Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status defne two distinct subtypes? Ann Oncol 24:283-291.
68. Whalley HC, Hall L, Romaniuk L, Macdonald A, Lawrie SM, Suss-mann JE, McIntosh AM (2014) Impact of cross-disorder poly-genic risk on frontal brain activation with specifc effect of schizophrenia risk. Schizophr Res 161: 484-489.
69. Wu RH, Feng C, Xu Y, Hua T, Liu XY, Fang M (2014) Late-onset depression in the absence of stroke: associated with silent brain infarctions, microbleeds and lesion locations. Int J Med Sci 11:587-592.
70. Xu HB, Zhang RF, Luo D, Zhou Y, Wang Y, Fang L, Li WJ, Mu J, Zhang L, Zhang Y, Xie P (2012) Comparative proteomic analysis of plasma from major depressive patients: identifcation of proteins associated with lipid metabolism and immunoregula-tion. Int J Neuropsychop 15:1413-1425.